Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling-Reference-Cited by-同舟云学术

Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling

Published:2020-07 Issue: Volume:150 Page:105317
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Kimura Koji^ORCID,Yoshida Atsushi,Katagiri Fumihiko^ORCID,Takayanagi Risa,Yamada Yasuhiko

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference57 articles.

1. Inflammatory bowel disease;Abraham;New Engl. J. Med.,2009

2. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis;Adedokun;Gastroenterology,2014

3. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease;Ainsworth;Am. J. Gastroenterol.,2008

4. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease;Baert;New Engl. J. Med.,2003

5. Review article: loss of response to anti-TNF treatments in Crohn’s disease;Ben-Horin;Aliment. Pharmacol. Ther.,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prediction method for the individual serum concentration and therapeutic effect for optimizing adalimumab therapy in inflammatory bowel disease;Journal of Pharmacy and Pharmacology;2024-07-15

2. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models;British Journal of Clinical Pharmacology;2024-06-06

3. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review;World Journal of Gastroenterology;2023-08-07

4. Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review;Pharmaceutics;2022-09-30

5. Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study;European Journal of Gastroenterology & Hepatology;2022-03-29